Article
MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2009
Yip Stephen, Miao Jiangyong, Cahill Daniel P, Iafrate A John, Aldape Ken, Nutt Catherine L, Louis David N
Abstract excerpt
PURPOSE: Over the past few years, the alkylating agent temozolomide has become the standard-of-care therapy for patients with glioblastoma, the most common brain tumor. Recently, large-scale cancer genome sequencing efforts have identified a hypermutation phenotype and inactivating MSH6 mismatch repair gene mutations in recurrent, post-temozolomide glioblastomas, particularly those growing more rapidly during...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.